The Human Microbiome is the group of loads of microbes living on and in the human body. The microbiomes are found, for example, in the skin, gut, mouth, and vagina. A live biotherapeutic product comprises a live microorganism used for the cure or treatment and prevention of disease. The live biotherapeutic industry is experiencing enormous research and development activities to develop products for various diseases and applications. The global market for live biotherapeutic products and microbiome contract manufacturing was valued at US$ 8.56 Mn in 2019, recording a promising CAGR of 47.54% during the period of 2021-2030.
Till now, about 200 companies are developing microbiome-based therapies anticipated to treat an extensive range of severe diseases, with big pharmaceutical companies showing augmented interest by associating with early innovators. Most of the clinical treatment is under the preclinical stage, various are under clinical development, and about 15 are in phase II/III trials of development. The commercialization of these products in the coming years is expected to generate a huge potential for the growth of the market over the estimated timeframe. However, the lack of a satisfactory manufacturing capacity of the innovators may significantly hinder the market's growth. Additionally, lack of the essential industry standards associated with live biotherapeutics manufacturing, batch-to-batch reliability-related concerns, lack of infrastructure, and uncertainties related to product approval and regulatory review are some of the factors affecting market growth substantially. However, a growing number of deals among various developers for contract manufacturing is projected to generate immense opportunities for the market's growth globally.
The Global Live Biotherapeutic Products and Microbiome Contract Manufacturing Market is segmented on the basis of product manufactured, type of formulation, the scale of operation, company size, and region. The market is divided into Active Pharmaceutical Ingredients (APIs) and Finished Drug Formulations (FDFs) based on the product manufactured. Based on the type of formulation, the market is segmented into solid formulations, oral liquids, injectables, and others. Based on the scale of operation, the market is categorized into, preclinical scale operations, clinical scale operations, and commercial-scale operations. By company size, live biotherapeutic products and microbiome contract manufacturing market is segmented into small-sized companies, mid-sized companies, and large companies. Based on the region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA.
The key players of this market include Quay Pharmaceuticals, Cobra Biologics Limited, Cerbios-Pharma SA, List Biological Labs, Inc., Arranta Bio, BacThera, Luina Bio Pty Ltd, 4D pharma plc, Paras Biopharmaceuticals Finland Oy, Capsugel, Deerland Probiotics & Enzymes, Paragon Bioservices, UAS Labs, Biose, Cobra Biologics, Cerbios, Inpac Probiotics, BJP Laboratories, S-Biomedic, Meteoric Biopharmaceuticals, BiomX, Universal Stabilization Technologies, Assembly Biosciences, Wacker Biotech, and Chung Mei Pharmaceutical. The live biotherapeutic products and microbiome contract manufacturing market has several players across the globe. The growing research and development activities and growing partnerships among the key players operating in the market to seek different companies' platforms are expected to boost the market significantly in the coming years.
